SCHEMBL5459052

SCHEMBL5459052

NC(=O)c1c(NC(=O)Nc2cccc(Cl)c2Cl)sc2c1CCCC2

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CFTR P13569 1/20 0.64
NPC1 O15118 6/20 0.61
RAB9A P51151 6/20 0.61
FLT3 P36888 11/20 0.60
MEN1 O00255 4/20 0.55
KMT2A Q03164 4/20 0.55
SMN1; SMN2 Q16637 3/20 0.55
ALDH1A1 P00352 3/20 0.55
HPGD P15428 2/20 0.55
LMNA P02545 2/20 0.55
KDM4E B2RXH2 1/20 0.55
ESR1 P03372 1/20 0.55
TP53 P04637 1/20 0.55
ALOX15 P16050 1/20 0.55
TSHR P16473 1/20 0.55
MAPK1 P28482 1/20 0.55
CASP1 P29466 1/20 0.55
HTT P42858 1/20 0.55
CASP7 P55210 1/20 0.55
HSD17B10 Q99714 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5449213 0.86 LMNA (0.48) CFTRNPC1RAB9AFLT3MEN1
SCHEMBL5455040 0.85 CFTR (0.55) CFTRNPC1RAB9AFLT3MEN1
SCHEMBL5423887 0.83 CFTR (0.63) CFTRNPC1RAB9AFLT3MEN1
SCHEMBL5445125 0.83 FLT3 (0.69) CFTRNPC1RAB9AFLT3MEN1
SCHEMBL17018738 0.81 KCNH2 (0.72) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL5446174 0.81 FLT3 (0.71) CFTRNPC1RAB9AFLT3MEN1
Hydrochloric Acid SCHEMBL17006396 0.80 KCNH2 (0.72) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL4234573 0.80 FLT3 (0.72) CFTRNPC1RAB9AFLT3MEN1
SCHEMBL5450860 0.79 MEN1 (0.78) CFTRNPC1RAB9AFLT3MEN1
SCHEMBL5460074 0.79 MEN1 (0.67) CFTRNPC1RAB9AFLT3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 CFTR 2030/4885NPC1 2627/4885RAB9A 948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.